You are here

Merck

FDA accepts new Keytruda data, opening door for wider indication

BioPharma Dive

Wed, 03/9/16 - 03:38 pm

metastatic non-small cell lung cancer

Sanofi and Merck pull the plug on European vaccines venture

Yahoo/Reuters

Tue, 03/8/16 - 10:19 am

Novo Nordisk Follows Eli Lilly as Worthy Rival to Merck in Diabetes

Bidness, ETC

Tue, 03/8/16 - 10:14 am

Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties

Bloomberg

Mon, 03/7/16 - 09:58 pm

Gilead Sciences

Why Is Remicade Driving Down Merck’s Immunology Franchise?

Yahoo/Market Realist

Sun, 03/6/16 - 02:56 pm

Keytruda: Merck’s New Blockbuster for Its Immuno-Oncology Franchise

Yahoo/Market Realist

Sun, 03/6/16 - 11:33 am

immuno-oncology

non-small cell lung cancer

Merck forges ahead with phase 3 trial of Humira biosimilar

BioPharma Dive

Fri, 03/4/16 - 02:00 pm

Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer

Yahoo

Thu, 03/3/16 - 10:44 am

clinical trials

Inside NanoString's deal with Merck: $12M in cash and a roadmap for expansion

Bizjournals.com

Wed, 03/2/16 - 11:44 am

NanoString Technologies

Drugmakers partner in immuno-oncology, to better capture market share

Medical Marketing and Media

Wed, 03/2/16 - 11:00 am

immuno-oncology

Bristol-Myers Squibb

Rivals chase Bristol-Myers in cancer immunotherapy drug race

Yahoo/Reuters

Fri, 02/26/16 - 11:09 am

Bristol-Myers Squibb

cancer immunotherapy

7 big pharma companies sign on to Parkinson's development group

BioPharma Dive

Wed, 02/24/16 - 11:49 am

Parkinson's Disease

Will Merck Encroach On Gilead's Harvoni Territory?

Yahoo/Benzinga

Tue, 02/23/16 - 05:44 pm

Merck CEO Kenneth Frazier talks about pricing, R&D—and why big pharmaceutical companies aren’t admired like they once were

Forbes

Mon, 02/22/16 - 09:43 am

Kenneth Frazier

A Look Back at 2 Successful Biotech Buyouts

Yahoo/GuruFocus

Mon, 02/22/16 - 09:37 am

Gilead Sciences

What Factors Impact Merck & Co.’s Revenues?

Yahoo/Market Realist

Thu, 02/18/16 - 09:19 pm

Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff

Fierce Pharma Marketing

Wed, 02/17/16 - 10:33 am

Express Scripts

Merck says U.S. FDA rejects its claim that Zetia and Vytorin cut heart risk

Yahoo/Reuters

Tue, 02/16/16 - 10:04 am

Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck

Motley Fool

Tue, 02/9/16 - 09:21 am

Gilead Sciences

How Analysts View Pfizer and Merck After Earnings

24/7 Wall St

Sun, 02/7/16 - 10:48 am

Pages